Copenhagen, 5 March 2015 Identification of the most immunogenic/protective VLP-HA construct in mice Department of Immunology Development of a universal.

Slides:



Advertisements
Similar presentations
FLUTCORE project meeting: WP3- Immunogenicity studies I-Na Lu PhD, CRP-Santé Group Leader: Prof. Dr. Claude Muller Institute of Immunology.
Advertisements

Lab of Immunoregulation
Clinical Outcomes of Influenza Infection Asymptomatic Asymptomatic Symptomatic Symptomatic  Respiratory syndrome - mild to severe  Involvement of major.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Epitope Selection Rational Vaccine design. Why? Therapeutic vaccines Therapeutic vaccines Treatment of viral infections (e.g., HIV, HCV), and resistant.
Pandemic Influenza Preparedness Kentucky Department for Public Health Department for Public Health.
4th Year MPharm SRP: Introduction to Pseudotype Viruses
$100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300.
Emerging Viruses BY PLAN A. Topic Questions  Why are these new viruses more harmful compared to the previous form of the virus?  Why is it so difficult.
BIRD FLU Prepared by: Haifa Al-Dhahri. Bird Flu(Avian influenza): Avian influenza viruses compose the Influenzavirus A genus of the Orthomyxoviridae family.
Ryan Kang Jeff Huynh Per. 5.  Virus  Subtype H5N1 influenza A strain  Usually unlikely to transfer from birds to humans  Human to Human infection.
London, 23 rd September 2015 B cell response and escape mutants Identification of protective hemagglutinin stalk-specific B cell receptor sequences Identification.
VRBPAC Topic #2: Clinical Development of Influenza Vaccines for Pre-pandemic Use Joseph G. Toerner, MD, MPH VCTB/DVRPA/OVRR/CBER/FDA February 27, 2007.
Mbio 451–Immunology Dr. Ayman Mubarak. Lecture time : Sun Tue 9:00 -9:50 a.m. Credits : 3 hrs (2+1) Useful Online resourse: 1-
John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group Five: Immunology, Assay Standardization,
Vaccines: A Molecular View
Seasonal and Pandemic Influenza Research Activities National Vaccine Advisory Committee Meeting September 27, 2006 Barbara L. Mulach, Ph.D. National Institute.
What Is H1N1 (Swine Flu) Pandemic Influenza? Colorized image of H1N1 from a transmission electron micrograph. Source: CDC.
Genetic DNA Vaccines By Chelsea Heimbrock. What are DNA Vaccines? An injection of genes of a virus into the body that creates an immune response for the.
Latvian Biomedical Research and Study Centre (BMC), Riga, Latvia.
Test of a new liposomal adjuvant for the commercial influenza vaccine in ferret Martel C. a, Hammer Jensen T. a, Viuff B. a, Nielsen L.P. b, Agger E.M.
RESULTS CONCLUSIONS Characterization of virus-like particle of Yellow fever virus in Drosophila expression system Characterization of virus-like particle.
Higher Affinity Heptapeptides Against Influenza Hemagglutinin-Sialic Acid Identification for Treating Flu Virus Disease Ahmed ”e” Al Qaffas.
? Neutralizing Antibodies: Research pathways in 2013 and beyond
Systems Vaccinology Immunity
Influenza Vaccines: Challenges and Solutions
Universal influenza virus vaccines and therapeutic antibodies
Phosphatase activity associated with Shp1 is reduced in Themis−/− thymocytes. Phosphatase activity associated with Shp1 is reduced in Themis−/− thymocytes.
Type 17 immunity is increased in STAT1−/− mice.
Targeted DNA vaccination induced protection against nasal challenge with influenza virus 14 d after DNA vaccination. Targeted DNA vaccination induced protection.
The PI3K–Akt pathway is essential for the in vivo maintenance of murine Tregs. The PI3K–Akt pathway is essential for the in vivo maintenance of murine.
Long-lasting protection against nasal challenge with influenza virus 252 d after a single DNA vaccination. Long-lasting protection against nasal challenge.
Protection from influenza virus challenge.

Serum neutralizing antibody response of BALB/c mice to DNA prime followed by VRP boost. Serum neutralizing antibody response of BALB/c mice to DNA prime.
Antibody endpoint titers induced by PfCelTOS vaccines containing various adjuvant formulations with emulsion doses of 0.5% to 2% (vol/vol) oil, as measured.
Longevity of mucosal and systemic antibody responses induced by pulmonary vaccination. Longevity of mucosal and systemic antibody responses induced by.
Modified at -
Immune response modifiers in the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy.
Duy T. Nguyen et al. JACEP 2017;3:
Chimeric HA-based universal influenza virus vaccine concept.
CANINE INFLUENZA VIRUS VACCINATION PROTOCOLS
PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.
Vaccine MN confer protective innate and adaptive immunity.
Schematic representation of the immunization regimens used in this study. Schematic representation of the immunization regimens used in this study. BALB/c.
Prime and boosts with PBK001 vaccine provided 100% protection with low bacterial burden in organs. Prime and boosts with PBK001 vaccine provided 100% protection.
Antibody endpoint titers induced by PfCelTOS vaccines containing various adjuvant formulations with emulsion doses of 0.02% to 2% (vol/vol) oil, as measured.
Positions of amino acids in NA that have changed since 2009.
Intranasal immunization of mice with S
Cross-protection against variants within a subtype after intranasal immunization with vaccine from MDCK cell-adapted Vac-3 P22. Cross-protection against.
Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.
Schematic representation of the progress in the development of vaccines against the most recent pandemic and seasonal H1N1 influenza virus strains. Schematic.
RTA pepscan analysis of sera from RiVax- and RVEc-immunized mice.
Functional characterization of multidonor class antibodies.
RTA-specific serum IgG antibody titers and TNA in mice immunized with RiVax or RVEc. RTA-specific serum IgG titers after the second (A) or third (B) immunizations.
Simplified representation of the reverse genetic approach used to construct the chimera vaccine Poulvac FluFend i AI H5N3 RG to protect poultry against.
LAIV and WT influenza virus infection similarly enhance 19F pneumococcal carriage density and duration of colonization. LAIV and WT influenza virus infection.
LAIV enhances bacterial load and duration of staphylococcal carriage.
Influenza vaccine enhances NK cell function through IFN-α.
Establishment of MajSAT RNA–expressing mice.
Effectiveness of vaccination for influenza in the current and any of the 3 previous seasons in preventing nonsevere and severe cases of influenza by season,
LAIV enhancement of pneumococcal density is time dependent and long lasting. LAIV enhancement of pneumococcal density is time dependent and long lasting.
Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.
Showing (A) the reported activity of community midwifery teams in recommending and providing seasonal influenza vaccination to pregnant women and (B) the.
Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.
Long-lived antibody-secreting cells in the bone marrow, induced by PfCelTOS vaccines containing various adjuvant formulations with emulsion doses of 0.02%
Long-lived antibody-secreting cells in the bone marrow, induced by PfCelTOS vaccines containing various adjuvant formulations with emulsion doses of 0.5%
Antigen-specific cytokine production detected by multiplex bead assay (Luminex) 3 weeks after the 3rd immunization. Antigen-specific cytokine production.
Differences in the relative abundances of mycobacteria (as determined via 16S rRNA gene sequencing) across households in the United States on municipal.
Patient flowchart for inclusion and analysis
Presentation transcript:

Copenhagen, 5 March 2015 Identification of the most immunogenic/protective VLP-HA construct in mice Department of Immunology Development of a universal influenza vaccine based on tandem core technology

Schematic of VLP-HA constructs Modified from Steel et al, mBio 2010 ΔHA stalk (HA ): GGGG

VLP-HA constructs ΔHA stalk (HA ): HA : HA : HA : LAH (HA ): HA : HA : HA : HA : HA :

Immune response to VLP-HAs

Immunization with VLP-Has protects mice in vivo ΔHA stalk (HA ): HA : HA : LAH (HA ):

IgG-specific antibody response of mice vaccinated with VLP-HAs ΔHA stalk (HA ): HA : HA : LAH (HA ):

HA (LAH) of different HA subtypes

Ongoing Work Immunization with new VLPs in mice In vivo challenge-protection assay with H3N2 Micro-neutralization and ADCC assays

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.